Atrial fibrillation and bisphosphonate therapy
- 1 January 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 25 (1) , 2-10
Abstract
Bisphosphonates are the most commonly used treatment for osteoporosis and have proven efficacy in the reduction of vertebral and nonvertebral fractures. Recently, concerns have been raised about a possible association between bisphosphonate therapy and atrial fibrillation (AF) following the report of a significant increase in risk of serious AF in women treated with zoledronic acid in the HORIZON study. Subsequent studies have produced conflicting results but have not excluded the possibility of such an association. Currently there is no direct evidence that bisphosphonates exert either acute or chronic effects on cardiac electrophysiology. Nevertheless, altered intracellular electrolyte homeostasis and proinflammatory, profibrotic, and antiangiogenic effects provide potential mechanisms by which atrial conduction could be affected in patients treated with bisphosphonates. In studies in which an increase in risk of AF has been identified, there is no evidence that this translates into increased mortality or increased risk of stroke, and the risk-benefit balance of bisphosphonate therapy in patients with osteoporosis and other forms of metabolic bone disease remains strongly positive. © 2010 American Society for Bone and Mineral ResearchKeywords
This publication has 70 references indexed in Scilit:
- Pharmacological changes in cellular Ca2+homeostasis parallel initiation of atrial arrhythmogenesis in murine langendorff‐perfused heartsClinical and Experimental Pharmacology and Physiology, 2009
- Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studiesBMC Musculoskeletal Disorders, 2009
- Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trialHeart, 2009
- Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety AnalysisPLOS ONE, 2009
- Bisphosphonates and Atrial FibrillationDrug Safety, 2009
- Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillationJournal of Molecular and Cellular Cardiology, 2008
- Calcium Handling Abnormalities in Atrial Fibrillation as a Target for Innovative TherapeuticsJournal of Cardiovascular Pharmacology, 2008
- Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ, 2008
- Status of the Epidemiology of Atrial FibrillationMedical Clinics of North America, 2008
- Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysisHeart, 2007